BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HealthLinx Appointment of Non Executive Chairman


2/22/2008 11:58:59 AM

21 February 2008, Melbourne: The Directors of HealthLinx Limited (ASX:HTX) are pleased to announce the appointment of Professor Gregory Rice as Non Executive Chairman of the Company.

Professor Rice is a co-founder of HealthLinx and a co-inventor of key patents that underpin HealthLinx’s product development goals. He was appointed as a director of the Company following the reverse acquisition of Cryptome Pharmaceuticals Limited on 14 February 2006 and has been a director since that time.

For the last 6 months, in addition to his role as a director, Professor Rice has also provided science and operations services to the Company under a separate contract and has agreed to continue providing those services for the foreseeable future.

Enquires: Nick Gatsios, HealthLinx Limited 03 9208 4200 Rudi Michelson (Monsoon Communications) 03 9620 3333

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are: Ovarian cancer diagnostic (OvPlex) targeting US$260m pa market Pregnancy diagnostic. This would be used in a woman’s first prenatal visit to identify whether she is at high risk of pregnancy complications. Currently there is no product on the market for early stages of pregnancy.

A biomarker is a specific biochemical in the body that is used to measure progress of disease or the effects of treatment.

HealthLinx targets important markets with unmet needs. HealthLinx is developing product applications to successful Phase II biomarker trials and will then seek to out-license to partners for upfront and milestone payments and royalties on sales.

The company also has significant IP in Protein Depletion Technologies (ClearIT™) that depletes serum and other biological fluids of high abundant proteins. HealthLinx offers a fee for service to access the Cryptomics Platform that screens and identifies bio-active peptides for nutraceutical, functional foods and biological applications.

www.healthlinx.com.au



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES